Emergent BioSolutions Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; the supplied filing text does not provide standalone fourth-quarter results. Amounts are in U.S. dollars.
Business context
Emergent is a life sciences company selling medical countermeasures and commercial products and providing contract development and manufacturing (CDMO) services. In Q4 2021 it reorganized into Government—Medical Countermeasures, Commercial, and Services—CDMO business lines, with R&D centralized. The U.S. government (USG) represented approximately 50% of 2021 revenue, down from 64% in 2020.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $1,792.7 million | $1,555.4 million | +15% |
| Product sales | $1,023.9 million | $989.8 million | +3% |
| CDMO revenue | $634.6 million | $450.5 million | +41% |
| Contracts and grants | $134.2 million | $115.1 million | +17% |
| Operating income | $352.6 million | $433.8 million | -19% |
| Net income | $230.9 million | $305.1 million | -24% |
| Diluted EPS | $4.27 | $5.67 | Lower |
| Cash from operations | $321.1 million | $536.0 million | Lower |
- Operating margin was approximately 19.7% versus 27.9% in 2020; net margin was approximately 12.9% versus 19.6% (calculated from reported figures).
- Revenue drivers included nasal naloxone products at $434.3 million, up 40%; anthrax vaccines at $259.8 million, down 30%; and ACAM2000 at $206.5 million, up 3%. Travel vaccine sales remained depressed by pandemic-related travel disruption.
- Cash and cash equivalents were $576.1 million at year-end, versus $621.3 million. Working capital was $898.3 million. The company reported $597.7 million of unused revolving-credit capacity.
- Debt was $849.6 million gross, including $396.6 million on the term loan and $450 million of 3.875% notes due 2028; the balance-sheet carrying amount was $841.0 million. No revolver borrowings were outstanding. The term loan and revolving facility mature in October 2023.
- Capital expenditures were $225.0 million, making operating cash flow less capital expenditures approximately $96.1 million. Financing cash outflow was $141.0 million, including $106.0 million of share repurchases.
- Current assets were $1,272.1 million and current liabilities $373.8 million. Near-term obligations included $124.3 million of $132.0 million in non-cancelable purchase commitments due within 12 months.
Material changes and unusual items
- CDMO revenue growth reflected a full year of pandemic-related customer activity. However, CDMO costs rose substantially, including a $41.5 million inventory write-off and remediation costs following cross-contamination at the Bayview facility. Management attributed weaker CDMO margins primarily to these items and remediation.
- Manufacturing of Johnson & Johnson COVID-19 vaccine drug substance at Bayview was temporarily stopped in April 2021 after a batch issue. The filing identifies manufacturing compliance as a material business risk.
- BARDA and Emergent mutually terminated the CIADM agreement and associated task orders in November 2021. Realizable task-order value fell from $650.8 million to $470.9 million, and base-contract value from $163.2 million to $140.5 million. The termination led to $55.2 million of contract-liability revenue recognition and a $38.0 million contract-asset write-off to R&D expense.
- Emergent recorded $41.7 million of goodwill impairment in its Commercial reporting unit. It also disclosed immaterial out-of-period accounting adjustments that increased 2021 net income by $5.3 million.
- Teva launched a generic naloxone nasal spray in December 2021; Sandoz began distributing an authorized generic. In February 2022, an appeals court affirmed the ruling against Emergent in the NARCAN 4 mg patent case; the company said it intended to seek rehearing.
- A material weakness in controls over accounting assessments for complex revenue arrangements was identified during 2021. Management reported remediation by year-end; management and the auditor concluded internal control over financial reporting was effective as of December 31, 2021. The financial statement audit opinion was unqualified.
Outlook, management commentary and risks
- The filing does not provide specific FY2022 revenue or earnings guidance. Management’s five-year strategic plan targets at least $2 billion in 2024 revenue and an adjusted EBITDA margin of 27%–30%, conditional on successful execution.
- Management expected limited travel-vaccine sales to resume in 2022, consistent with a limited anticipated return to international travel. It also disclosed approximately $1.3 billion of revenue associated with remaining performance obligations, with a majority expected within 24 months; timing depends on manufacturing, customer demand, regulatory compliance, and government funding.
- Key exposures include reliance on USG procurement and appropriations, AV7909’s pending FDA approval, fixed-price contract execution, facility quality and production risks, COVID-19 demand and supply-chain uncertainty, and single-source suppliers.
- Additional risks include NARCAN generic and branded competition, ongoing shareholder litigation and government inquiries tied to COVID-19 vaccine manufacturing disclosures, substantial debt and covenant requirements, and potential collection, regulatory, and reputational impacts. The company said litigation losses could not be reasonably estimated.
Most important facts for investors to verify
- Whether AV7909 receives FDA approval and the timing, volume, and funding of future USG anthrax-vaccine orders.
- Bayview’s remediation, regulatory status, manufacturing performance, and any further effect on J&J or other CDMO work.
- Whether CDMO revenue and margins remain sustainable after the CIADM termination and changes in COVID-19 customer demand.
- The realized effect of generic competition on NARCAN sales and pricing, including the status of patent proceedings.
- Cash generation, capital spending, purchase commitments, debt repayment and refinancing needs, and compliance with credit covenants.
- Developments in shareholder litigation and government investigations, and any subsequent costs or disclosures regarding the remediated revenue-accounting weakness.